Impel NeuroPharma enrolls last patient in phase 3 migraine trial of INP104

This article was originally published here

STOP-301 is evaluating the safety of long-term, intermittent use of INP104 for 24-week and 52-week data points and will also collect efficacy data of INP104 as assessed by

The post Impel NeuroPharma enrolls last patient in phase 3 migraine trial of INP104 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply